ProfileGDS5678 / 1420272_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 25% 25% 28% 27% 24% 25% 37% 24% 24% 25% 31% 25% 25% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5876224
GSM967853U87-EV human glioblastoma xenograft - Control 22.5835125
GSM967854U87-EV human glioblastoma xenograft - Control 32.5843625
GSM967855U87-EV human glioblastoma xenograft - Control 42.5907228
GSM967856U87-EV human glioblastoma xenograft - Control 52.5678927
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6335624
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6084625
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8260337
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5418524
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5442924
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5724525
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6717131
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5736225
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5760525